• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Bevacizumab: New Standard for Non-Small Cell Lung Cancer?

  • in Oncology
  • — 16 Mar, 2008
Bevacizumab: New Standard for Non-Small Cell Lung Cancer?
AudioMedica News
Bevacizumab: New Standard for Non-Small Cell Lung Cancer?
Bevacizumab: New Standard for Non-Small Cell Lung Cancer?
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-416"/>
Christian Manegold
Christian Manegold
Nick Thatcher
Nick Thatcher
Christian Manegold, Heidelberg University Medical Center, Manheim
Nick Thatcher, Christie Hospital, Manchester

Is bevacizumab a new standard of care for patients with unresectable non-small cell lung cancer who have good performance status? This question was raised in a debate at the European Congress on Lung Cancer held in Turin. Christian Manegold provided delegates with evidence from the AVAil and ECOG 4599 studies which underpin current approval of this anti-vascular endothelial growth factor (VEG-F) antibody. Nick Thatcher pointed out the limitations. They both talked with Peter Goodwin.



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/080316_manegold_thatcher.mp3]

You may also like...

  • Keith Flaherty Advanced, unresectable melanoma: survival rates at five years doubled with ipilimumab therapy 26 Oct, 2013
  • John Gribben Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically 9 Aug, 2013
  • Dana Tsui Blood test for free tumour DNA could guide breast cancer therapy 3 Apr, 2013
  • Mario Sznol PD 1 inhibitor nivolumab shows promising activity in metastatic melanoma 21 Sep, 2013

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Cetuximab Extends Survival In Advanced Non-Small Cell Lung Cancer
  • Next story Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Which New Combination for Metastatic Renal Cell Cancer?
    • Pembrolizumab: No Survival Gains Second Line In…
    • Two Drug Combination Doubled Kidney Cancer…
    • Microbiome Diversity Key To Survival After…
  • Home
  • Oncology
  • Bevacizumab: New Standard for Non-Small Cell Lung Cancer?

© COPYRIGHT 2020 AUDIOMEDICA.COM.